Plain-English translation of NCT06462248 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing anti-CD19 CAR-T cell therapy, a treatment that takes your own immune cells, modifies them in a lab to recognize and fight cancer cells, and then returns them to your body. The study is designed for children and adults whose blood cancer has come back or stopped responding to standard treatments like chemotherapy.
Many patients with relapsed or hard-to-treat blood cancers do not respond well to standard chemotherapy alone. This medication represents a newer approach that harnesses your body's own immune system to target and destroy cancer cells, offering hope for patients who have limited options.
You likely qualify if…
You likely don't qualify if…
You will first undergo a procedure called lymphapheresis, where blood is drawn through a central line to collect your immune cells. Those cells are then sent to a lab where they are modified using the CliniMACS prodigy system to recognize and attack cancer cells. Once ready, you will receive conditioning chemotherapy followed by a single infusion of your modified cells back into your body. You will remain in the hospital for at least 7 days after the infusion for close monitoring of how your body responds to the treatment.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
China